Latest Sales Growth News

The Calmer Co. International Limited has reported an 81% surge in retail sales through Coles in July, driven by a significant expansion in store presence and strong consumer demand for its natural relaxation products.

Nutritional Growth Solutions revises its Q2 FY25 financials, confirming stable revenue and detailing expanded distribution into CVS and Walmart. The company is actively raising capital to support growth and improve liquidity.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Coventry Group’s FY25 results reveal a sharp EBITDA decline amid ERP disruptions and soft markets, prompting a major cost reduction drive for FY26.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Briscoe Group Limited reported a 2.07% increase in second quarter sales to $192.9 million, with online sales approaching 20% of total revenue. Despite ongoing economic challenges, the company expects a net profit after tax of at least $29 million for the first half of 2025.

MC Mining reports zero lost time injuries and steady progress on its flagship Makhado Project, while Uitkomst Colliery implements a turnaround plan that boosts sales despite production challenges.

BirdDog Technology Limited reported a 6.9% increase in quarterly sales to A$4.3 million, driven by the successful launch of two next-generation broadcast products and a strong cash position ahead of a planned share buy-back.

Unibail-Rodamco-Westfield reports robust H1-2025 results with tenant sales growth, portfolio valuation gains, and strategic brand expansion underpinning confidence in full-year earnings guidance.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.

Botanix Pharmaceuticals confirms material sales and prescription growth data, explaining the timing of its ASX disclosures amid share price fluctuations.

Michael Hill International reports flat full-year earnings and sales for FY25, with a second-half sales uptick and strategic store closures shaping its outlook.